Literature DB >> 14766206

Divergent effects of alpha1-antitrypsin on neutrophil activation, in vitro.

Sabina Janciauskiene1, Inga Zelvyte, Lennart Jansson, Tim Stevens.   

Abstract

alpha1-Antitrypsin (AAT) is a major circulating serine proteinase inhibitor in humans. The anti-proteinase activity of AAT is inhibited by chemical modification. These include inter- or intramolecular polymerisation, oxidation, complex formation with target proteinases (e.g., neutrophil elastase), and/or cleavage by multi-specific proteinases. In vivo, several modified forms of AAT have been identified which stimulate biological activity in vitro unrelated to inhibition of serine proteinases. In this study we have examined the effects of native and polymerised AAT and C-36 peptide, a proteolytic cleavage product of AAT, on human neutrophil activation, in vitro. We show that the C-36 peptide displays striking concentration-dependent pro-inflammatory effects on human neutrophils, including induction of neutrophil chemotaxis, adhesion, degranulation, and superoxide generation. In contrast to C-36 peptide, native and polymerised AAT at similar and higher concentrations showed no effects on neutrophil activation. These results suggest that cleavage of AAT may not only abolish its proteinase inhibitor activity, but can also generate a powerful pro-inflammatory activator for human neutrophils.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14766206     DOI: 10.1016/j.bbrc.2004.01.055

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  16 in total

Review 1.  Lung disease associated with alpha1-antitrypsin deficiency.

Authors:  Rubin M Tuder; Sabina M Janciauskiene; Irina Petrache
Journal:  Proc Am Thorac Soc       Date:  2010-11

2.  Acute-phase protein α1-antitrypsin inhibits neutrophil calpain I and induces random migration.

Authors:  Mariam Al-Omari; Elena Korenbaum; Matthias Ballmaier; Ulrich Lehmann; Danny Jonigk; Dietmar J Manstein; Tobias Welte; Ravi Mahadeva; Sabina Janciauskiene
Journal:  Mol Med       Date:  2011-04-11       Impact factor: 6.354

Review 3.  Protein misfolding and the serpinopathies.

Authors:  Didier Belorgey; Peter Hägglöf; Susanna Karlsson-Li; David A Lomas
Journal:  Prion       Date:  2007-01-06       Impact factor: 3.931

Review 4.  Immune-modulating effects of alpha-1 antitrypsin.

Authors:  Mario R Ehlers
Journal:  Biol Chem       Date:  2014-10       Impact factor: 3.915

5.  Effects of alpha 1-antitrypsin on endotoxin-induced lung inflammation in vivo.

Authors:  Devipriya Subramaniyam; Chad Steele; Thomas Köhnlein; Tobias Welte; Olof Grip; Sadis Matalon; Sabina Janciauskiene
Journal:  Inflamm Res       Date:  2010-03-18       Impact factor: 4.575

Review 6.  Expanding the clinical indications for α(1)-antitrypsin therapy.

Authors:  Eli C Lewis
Journal:  Mol Med       Date:  2012-09-07       Impact factor: 6.354

Review 7.  The Serpin Superfamily and Their Role in the Regulation and Dysfunction of Serine Protease Activity in COPD and Other Chronic Lung Diseases.

Authors:  Gillian A Kelly-Robinson; James A Reihill; Fionnuala T Lundy; Lorcan P McGarvey; John C Lockhart; Gary J Litherland; Keith D Thornbury; S Lorraine Martin
Journal:  Int J Mol Sci       Date:  2021-06-14       Impact factor: 5.923

8.  The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency.

Authors:  S T Schmid; J Koepke; M Dresel; A Hattesohl; E Frenzel; J Perez; D A Lomas; E Miranda; T Greulich; S Noeske; M Wencker; H Teschler; C Vogelmeier; S Janciauskiene; A R Koczulla
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-09-28

9.  alpha1-antitrypsin and its C-terminal fragment attenuate effects of degranulated neutrophil-conditioned medium on lung cancer HCC cells, in vitro.

Authors:  Inga Zelvyte; Tim Stevens; Ulla Westin; Sabina Janciauskiene
Journal:  Cancer Cell Int       Date:  2004-11-21       Impact factor: 5.722

10.  C-Terminal Alpha-1 Antitrypsin Peptide: A New Sepsis Biomarker with Immunomodulatory Function.

Authors:  Nancy Blaurock; Diana Schmerler; Kerstin Hünniger; Oliver Kurzai; Katrin Ludewig; Michael Baier; Frank Martin Brunkhorst; Diana Imhof; Michael Kiehntopf
Journal:  Mediators Inflamm       Date:  2016-06-13       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.